Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP786874.RAEQcPmdE8whVhXkp61oq-sUMCm6ifEfONNTVo7DXIvAw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP786874.RAEQcPmdE8whVhXkp61oq-sUMCm6ifEfONNTVo7DXIvAw130_assertion type Assertion NP786874.RAEQcPmdE8whVhXkp61oq-sUMCm6ifEfONNTVo7DXIvAw130_head.
- NP786874.RAEQcPmdE8whVhXkp61oq-sUMCm6ifEfONNTVo7DXIvAw130_assertion description "[The aim of this study was to evaluate the response and resistance of cases to chronic myeloid leukemia (CML) therapy with tyrosine kinase (TK) inhibitors (imatinib mesylate) and to search for mutations in the breakpoint cluster region (BCR)-Abelson murine leukemia (ABL) kinase domain prior to and during therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP786874.RAEQcPmdE8whVhXkp61oq-sUMCm6ifEfONNTVo7DXIvAw130_provenance.
- NP786874.RAEQcPmdE8whVhXkp61oq-sUMCm6ifEfONNTVo7DXIvAw130_assertion evidence source_evidence_literature NP786874.RAEQcPmdE8whVhXkp61oq-sUMCm6ifEfONNTVo7DXIvAw130_provenance.
- NP786874.RAEQcPmdE8whVhXkp61oq-sUMCm6ifEfONNTVo7DXIvAw130_assertion SIO_000772 19943786 NP786874.RAEQcPmdE8whVhXkp61oq-sUMCm6ifEfONNTVo7DXIvAw130_provenance.
- NP786874.RAEQcPmdE8whVhXkp61oq-sUMCm6ifEfONNTVo7DXIvAw130_assertion wasDerivedFrom befree-20140225 NP786874.RAEQcPmdE8whVhXkp61oq-sUMCm6ifEfONNTVo7DXIvAw130_provenance.
- NP786874.RAEQcPmdE8whVhXkp61oq-sUMCm6ifEfONNTVo7DXIvAw130_assertion wasGeneratedBy ECO_0000203 NP786874.RAEQcPmdE8whVhXkp61oq-sUMCm6ifEfONNTVo7DXIvAw130_provenance.